Copeptin Levels Before and After Transsphenoidal Surgery for Cushing Disease: A Potential Early Marker of Remission
- PMID: 35528828
- PMCID: PMC9070476
- DOI: 10.1210/jendso/bvac053
Copeptin Levels Before and After Transsphenoidal Surgery for Cushing Disease: A Potential Early Marker of Remission
Abstract
Context: Arginine-vasopressin and CRH act synergistically to stimulate secretion of ACTH. There is evidence that glucocorticoids act via negative feedback to suppress arginine-vasopressin secretion.
Objective: Our hypothesis was that a postoperative increase in plasma copeptin may serve as a marker of remission of Cushing disease (CD).
Design: Plasma copeptin was obtained in patients with CD before and daily on postoperative days 1 through 8 after transsphenoidal surgery. Peak postoperative copeptin levels and Δcopeptin values were compared among those in remission vs no remission.
Results: Forty-four patients (64% female, aged 7-55 years) were included, and 19 developed neither diabetes insipidus (DI) or syndrome of inappropriate anti-diuresis (SIADH). Thirty-three had follow-up at least 3 months postoperatively. There was no difference in peak postoperative copeptin in remission (6.1 pmol/L [4.3-12.1]) vs no remission (7.3 pmol/L [5.4-8.4], P = 0.88). Excluding those who developed DI or SIADH, there was no difference in peak postoperative copeptin in remission (10.2 pmol/L [6.9-21.0]) vs no remission (5.4 pmol/L [4.6-7.3], P = 0.20). However, a higher peak postoperative copeptin level was found in those in remission (14.6 pmol/L [±10.9] vs 5.8 (±1.4), P = 0.03]) with parametric testing. There was no difference in the Δcopeptin by remission status.
Conclusions: A difference in peak postoperative plasma copeptin as an early marker to predict remission of CD was not consistently present, although the data point to the need for a larger sample size to further evaluate this. However, the utility of this test may be limited to those who develop neither DI nor SIADH postoperatively.
Keywords: Cushing disease; copeptin; cortisol; remission.
Published by Oxford University Press on behalf of the Endocrine Society 2022.
Figures







Similar articles
-
Postsurgical utility of copeptin for the prediction of postoperative arginine vasopressin deficiency.J Neurosurg. 2023 Nov 10;140(5):1276-1284. doi: 10.3171/2023.8.JNS23418. Print 2024 May 1. J Neurosurg. 2023. PMID: 37948691
-
Postoperative Copeptin Concentration Predicts Diabetes Insipidus After Pituitary Surgery.J Clin Endocrinol Metab. 2015 Jun;100(6):2275-82. doi: 10.1210/jc.2014-4527. Epub 2015 Apr 29. J Clin Endocrinol Metab. 2015. PMID: 25923040
-
Postoperative Copeptin as a Biomarker for Development of Diabetes Insipidus Following Hypothalamic-Pituitary Surgery.Endocr Pract. 2021 May;27(5):463-470. doi: 10.1016/j.eprac.2020.11.015. Epub 2020 Dec 15. Endocr Pract. 2021. PMID: 33645512
-
Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction.Neuropeptides. 2021 Oct;89:102167. doi: 10.1016/j.npep.2021.102167. Epub 2021 Jun 24. Neuropeptides. 2021. PMID: 34175655 Review.
-
Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis.Clin Endocrinol (Oxf). 2019 Jul;91(1):22-32. doi: 10.1111/cen.13991. Epub 2019 May 8. Clin Endocrinol (Oxf). 2019. PMID: 31004513 Free PMC article. Review.
Cited by
-
Pitfalls in the Diagnosis and Management of Hypercortisolism (Cushing Syndrome) in Humans; A Review of the Laboratory Medicine Perspective.Diagnostics (Basel). 2023 Apr 14;13(8):1415. doi: 10.3390/diagnostics13081415. Diagnostics (Basel). 2023. PMID: 37189516 Free PMC article. Review.
References
-
- Kaiser U, Ho KKY. Chapter 8: pituitary physiology and diagnostic evaluation. In: Melmed S, Larsen PR, Kronenberg H, eds. Williams Textbook of Endocrinology, P.K. Elsevier: Philadelphia; 2016:176–231.
-
- Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101. - PubMed
LinkOut - more resources
Full Text Sources